Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignancies

Clinical Cancer Research

Volumn 17, Issue 9, 2011, Pages 2997-3004

  Weiss, Glen J ^a   Infante, Jeffrey R ^c   Chiorean, E Gabriela ^d   Borad, Mitesh J ^a,b   Bendell, Johanna C ^c   Molina, Julian R ^e   Tibes, Raoul ^a   Ramanathan, Ramesh K ^a   Lewandowski, Karen ^a   Jones, Suzanne F ^c   Lacouture, Mario E ^f   Langmuir, Virginia K ^g   Lee, Hank ^g   Kroll, Stew ^g   Burris III, Howard A ^c  

^a Virginia G Piper Cancer Center   (United States)

^b MAYO CLINIC   (United States)

^c SARAH CANNON RESEARCH INSTITUTE   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e MAYO CLINIC CANCER CENTER   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g Threshold Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; TH 302; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BACKACHE; COLORECTAL CANCER; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEMALE; HEAD AND NECK CANCER; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MUCOSAL DISEASE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVARY CANCER; OXIDATION; PANCREAS CANCER; PANCREAS CARCINOMA; PANCYTOPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROCTITIS; PROSTATE CANCER; SKIN TOXICITY; STOMATITIS; THROMBOCYTOPENIA; VAGINITIS; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CELL HYPOXIA; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MODELS, BIOLOGICAL; NEOPLASMS; NITROIMIDAZOLES; PHOSPHORAMIDE MUSTARDS; PRODRUGS;

EID: 79955490434     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-3425     Document Type: Article

References (24)

1. Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 2004;4:437-47. (Pubitemid 38745529)
2. Hockel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biological, and molecular aspects. J Natl Cancer Inst 2001;93:266-76. (Pubitemid 32219813)
3. Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer 2006;6:583-92. (Pubitemid 44140857)
4. Lu X, Kang Y. Hypoxia and hypoxia-inducible factors: master regulators of metastasis. Clin Cancer Res 2010;16:5928-35.
5. Shulman LN, Buswell L. Phase I trial of the hypoxic cell cytotoxin tirapazamine with concurrent radiation therapy in the treatment of refractory solid tumors. Int J Radiation Oncology Biol Phys 1999;44:349-53. (Pubitemid 29205033)
6. Albertella MR, Loadman PM, Jones PH, Phillips RM, Rampling R, Burnet N, et al. Hypoxia-selective targeting by the bioreductive prodrug AQ4N in patients with solid tumors: results of a phase 1 study. Clin Cancer Res 2008;14:1096-104. (Pubitemid 351302556)
7. Patterson AV, Ferry DM, Edmunds SJ, Gu Y, Singleton RS, Patel K, et al. Mechanism of action and preclinical antitumor activity of the novel hypoxia activated DNA cross-linking agent PR-104. Clin Cancer Res 2007;13:3922-32. (Pubitemid 47037600)
8. Duan JX, Jiao H, Kaizerman J, Stanton T, Evans JW, Lan L, et al. Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugs. J Med Chem 2008;51:2412-20. (Pubitemid 351628502)
9. Denny WA, Wilson WR. Considerations on the design of nitrophenyl mustards as agents with selective toxicity for hypoxic tumour cells. J Med Chem 1986;29:879-87. (Pubitemid 16068792)
10. Raleigh JA, Thrall DE, Varia MA. Development and clinical application of pimonidazole as a marker for tumor hypoxia. Recent Res Dev Cancer 2001;3:189-210.
11. Hart CP, Armstrong AJ, Chiorean EG, Sun JD, Langmuir VK, Meng F, et al. Bench to bedside experience with TH-302: a tumor-selective hypoxia-activated prodrug as a promising treatment for prostate cancer. Proceedings of the AACR Annual Meeting; 2009. Abstract B185.
12. Ahluwalia D, Sun JD, Liu Q, Ferraro DJ, Wang Y, Lewis JG, et al. TH- 302, a novel hypoxia-activated prodrug, shows superior efficacy and less toxicity than ifosfamide (IFOS) in metastatic and ectopic human lung carcinoma models. Proceedings of the AACR Annual Meeting ; 2009 Apr 18-22; Denver, CO. Abstract 4517.
13. Hu J, Handisides DR, Van Valckenborgh E, De Raeve H, Menu E, Vande Broek I, et al. Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug. Blood 2010;116:1524-7.
14. Simon R, Freidlin B, Rubinstein L, Arbuck SG, Collins J, Christian MC, et al. Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 1997;89:1138-47. (Pubitemid 27337928)
15. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
16. McKeown SR, Coweny RL, Williams KJ. Bioreductive drugs: from concept to clinic. Clin Oncol 2007;19:427-42. (Pubitemid 46995614)
17. Senan S, Rampling R, Graham MA, Wilson P, Robin H, Eckardt N, et al. Phase I and pharmacokinetic study of tirapazamine (SR 4233) administered every three weeks. Clin Cancer Res 1997;3:31-8. (Pubitemid 27079441)
18. Doherty N, Hancock SL, Kaye S, Coleman CN, Shulman L, Marquez C, et al. Muscle cramping in Phase I clinical trials of tirapazamine (SR 4233) with and without radiation. Int J Radiat Oncol Biol Phys 1994;29;379-82. (Pubitemid 24166550)
19. Patterson LH, McKeown SR. AQ4N: a new approach to hypoxiaactivated cancer chemotherapy. Br J Cancer 2000;83:1589-93, (Pubitemid 32001698)
20. Papadopoulos KP, Goel S, Beeram M, Wong A, Desai K, Haigentz M, et al. A phase 1 open-label, accelerated dose-escalation study of the hypoxia-activated prodrug AQ4N in patients with advanced malignancies. Clin Cancer Res 2008;14:7110-5.
21. Melink TJ, Jameson MB, McKeage MJ, Guthiel JC. A phase I pharmacokinetic study of PR-104, a hypoxia-activated nitrogen mustard prodrug administered on a weekly schedule in patients with solid tumors. J Clin Oncol 2008;26:abstr 14543.
22. Jameson MB, Rischin D, Pegram M, Guthiel JC, Patterson A, Denny W, et al. A phase I pharmacokinetic study of PR-104, a hypoxiaactivated nitrogen mustard prodrug, in patients with solid tumors. J Clin Oncol 2008;26:abstr 2562.
23. Evans SM, Schrlau AE, Chalian AA, Zhang P, Koch CJ. Oxygen levels in normal and previously irradiated human skin as assessed by EF5 binding. J Invest Derm 2006;126:2596-606. (Pubitemid 44764043)
24. Taylor CT, Colgan SP. Hypoxia and gastrointestinal disease. J Mol Med 2007;85:1295-300. (Pubitemid 50004090)